For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (752)
-
July 14, 2025 | Official Statement Mylan says Amgen's US court loss against Regeneron shows bundles rebates can be anticompetitive
...told a US federal judge that a recent decision against Amgen supports maintaining its claims against Sanofi-Aventis...
Sections: Antitrust
-
July 10, 2025 | Official Statement Sanofi-Blueprint Medicines deal received US antitrust clearance
...MLex Summary: The US waiting period for Sanofi's acquisition of Blueprint Medicines for $9.5 billion...
Sections: DealRisk® and Mergers and Acquisitions
-
July 10, 2025 | Insight Sanofi receives US green light for Blueprint Medicines buyout
...Sanofi’s acquisition of Blueprint Medicines for about $9 billion has received clearance from the US antitrust...
Sections: DealRisk® and Mergers and Acquisitions
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
Already a subscriber? Click here to login